Business
GeoVax Announces Upcoming Presentations at Scientific Conferences
ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human
About this update from Geovax Labs, Inc.
[{"type":"text","content":"ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it will be represented during presentations at the following upcoming scientific conferences. Vaccine World Asia Congress & Global COVID-19 Vaccine Manufacturing & Supply Chain Summit (virtual conference), November 17-18 On November 17, Mark Newman, PhD, GeoVax Chief Scientific Officer, will deliver a presentation entitled, Addressing Evolving SARS-CoV-2 Variants through a Universal Coronavirus Vaccine. World Vaccine & Immunotherapy Congress West Coast 2021, San Diego, CA, Nov 30 – Dec 2 On November 30, Mark Newman, PhD, GeoVax Chief Scientific Officer, will participate in an expert panel discussion on design approaches to produce a universal SARS-CoV-2 vaccine and deliver a presentation on the topic, VLP-based COVID-19 vaccine development. On December 2, Mary Hauser, PhD, GeoVax Senior Scientist, will deliver a presentation entitled, Design and Evaluation of Vaccines Against Hemorrhagic Fevers using the MVA-VLP Platform. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using novel patented platforms. GeoVax’s Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform utilizes MVA, a large virus capable of carrying several vaccine antigens, that expresses proteins that assemble into VLP immunogens in the person receiving the vaccine. The production of VLP in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s MVA-VLP development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the A...